Based on these findings, we hypothesized that the CtBP2-G9a interaction cooperates to drive CRC progression and that pharmacological or genetic disruption of this interface may restore tumor-suppressor gene expression and attenuate malignant proliferation. The gene discussed is EHMT2; the disease is neoplasm.